Mo FR, et al. - Researchers conducted a network meta-analysis to assess the effectiveness and safety of all available antithrombotic therapies for secondary prevention following acute coronary syndrome. Findings suggest non-inferiority of an aspirin + new P2Y12 inhibitor converted to clopidogrel treatment strategy compared to aspirin + new P2Y12 inhibitor. They noted the conversion strategy can probably reduce the risk of myocardial infarction further without an increase in the risk of bleeding vs aspirin + clopidogrel. Treatment with aspirin + new P2Y12 inhibitors may reduce the risk of death vs aspirin + clopidogrel. With rivaroxaban + new P2Y12 inhibitor therapy, major cardiovascular events, all-cause deaths, cardiac deaths, myocardial infarction, clinically significant bleeding, and major bleeding risk were not significantly different vs aspirin + new P2Y12 inhibitor.